Monday (29.10.2018)

07:30 – 09:00

Room: Großer Saal

Scientific Session Advanced Stages

  • Volker Diehl
  • Peter Johnson
  • 07:30–07:50

    ECHELON1 Update

    • John Radford
  • 07:50–08:10

    HD18 Update

    • Peter Borchmann
  • 08:10–08:30

    LYSA AHL2011 Phase III Study

    • Olivier Casasnovas
  • Abstract Talk

    Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816

      Chul Ha
  • Abstract Talk

    Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)

      Sally Barrington
  • Abstract Talk

    B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

      Alexander Fossa

09:15 – 10:15

Room: Großer Saal

Scientific Symposium (by Celgene GmbH) CAR T Cell Therapies: Hype Or Hope?

  • Hermann Einsele
  • 09:15–09:35

    Preclinical Rationale for CAR T Cell Therapy

    • Simone Thomas
  • 09:35–09:55

    CD19 directed CAR T Cell Therapy in B-NHL

    • Peter Borchmann
  • 09:55–10:15

    BCMA directed CAR T Cell Therapy in MM

    • Hermann Einsele

10:30 – 12:00

Room: Großer Saal

Scientific Session Pediatric HL

  • Kara Kelly
  • Christine Mauz-Körholz
  • 10:30–10:50

    PD1/-L1 Expression in Pediatric HL

    • Stefan Gattenlöhner
  • 10:50–11:10

    Genotyping in Familial HL

    • Jun Yang
  • 11:10–11:30

    Functional and Financial outcomes after Treatment for Pediatric Hodgkin Lymphoma

    • Susan Parsons
  • Abstract Talk

    Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A pooled analysis of contemporary Children’s Oncology Group trials

      Justine Kahn
  • Abstract Talk

    Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA / COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)

      Monika Metzger
  • Abstract Talk

    The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study

      Maja Maraldo

12:15 – 13:45

Room: Großer Saal

Scientific Symposium (by MSD) Checkpointblockade in Lymphomas

  • Andreas Engert
  • 12:15–12:35

    Basics in immunotherapy for lymphomas

    • Dominik Wolf
  • 12:35–12:55

    PD-1 blockade current and future aspects of cHL therapy

    • Peter Borchmann
  • 12:55–13:15

    PD-1 blockade in NHLs

    • Pier Luigi Zinzani

14:00 – 15:30

Room: Großer Saal

Scientific Session Immunotherapy – Clinical

  • Philippe Armand
  • Martin Hutchings
  • 14:00–14:20

    Checkmate 205: Cohort D

    • Stephen Ansell
  • 14:20–14:40

    Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up

    • Paul J. Bröckelmann
  • Abstract Talk

    Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study

      Alex Herrera
  • Abstract Talk

    A Phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese Patients with Relapsed/Refractory classic Hodgkin Lymphoma

      Jun Zhu
  • Poster Pitch

    A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results

      Jane Winter
  • Abstract Talk

    Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

      Jonathan Friedberg
  • Abstract Talk

    Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate

      Carmelo Carlo-Stella

15:30 – 16:00

Room: Kleiner Saal

Main Program Poster Session

16:00 – 17:30

Room: Großer Saal

Scientific Session Relapsed/Refractory HL

  • Craig H. Moskowitz
  • Anna Sureda
  • 16:00–16:20

    Transplant BRaVE : Phase II trial

    • Anton Hagenbeek
  • 16:20–16:40

    Novel Agents in First Line Salvage

    • Ranjana Advani
  • Abstract Talk

    Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

      Carmen Martinez
  • Abstract Talk

    Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group

      Ewa Paszkiewicz-Kozik
  • Poster Pitch

    Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)

      Catherine Diefenbach
  • Poster Pitch

    PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation

      Anna Sureda
  • Abstract Talk

    Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).

      Craig H. Moskowitz
  • Abstract Talk

    Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome

      Paul J. Bröckelmann

17:30 – 18:15

Room: Großer Saal

Main Program Closing Remarks

  • Andreas Engert

ISHL11 Program at a glance

ISHL11 Program at a glance